Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | FHA-11 KRAS G12V-TCR |
| Synonyms | |
| Therapy Description |
Limited information is currently available on FHA-11 KRAS G12V-TCR, a putative T-cell therapy targeting KRAS G12V (Apr 2024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| FHA-11 KRAS G12V-TCR | FHA-11KRAS G12V-TCR | Limited information is currently available on FHA-11 KRAS G12V-TCR, a putative T-cell therapy targeting KRAS G12V (Apr 2024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06043713 | Phase I | Bendamustine FHA-11 KRAS G12V-TCR Cyclophosphamide + Fludarabine | Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations | Suspended | USA | 0 |